Robert Tam PhD
Robert Tam has served as Vice President, Program Management since June 2020. Robert has over 27 years of pharmaceutical drug development experience covering drug discovery through to NDA submission. During this period, he has accrued 20 years of portfolio, alliance and program management expertise, of which the last 12 years has been in oncology drug development. Prior to joining Bright Peak, Robert served as Executive Director, Program and Alliance Management at Mirati Therapeutic where he led the development of small molecule inhibitors of tumor-specific mutations (including KRAS G12C program) from preclinical candidate to phase 2 while managing 4 global alliance partnerships. Before that, he was Senior Director, Program Management at Agensys In., a subsidiary of Astellas Pharma Inc. From 2009 – 2017, he and his team were responsible for managing the development of the portfolio of antibody-drug conjugates (ADC) for various oncology indications at Agensys, from discovery through to clinical proof-of-concept. Robert received his PhD working on erythropoietin research at Kings College, University of London, UK followed by a postdoctoral fellowship in immunology at University of California, San Francisco.